Highlights

• Recce signed an exclusive agreement with Arrotex for R327G commercialisation in Australia and New Zealand.

• Arrotex will handle product registration, market access, Marketing and sales costs within the licensed territories.

• Recce retains product manufacturing, Supply rights and ownership of the underlying intellectual property under the commercial agreement.

• The agreement covers diabetic foot infections and acute bacterial skin and skin structure infections in the licensed regional markets.

A new commercial Partnership has put the regional future of R327G at the forefront for Recce Pharmaceuticals Ltd (ASX:RCE). The biotechnology developer agreed to an exclusive licensing arrangement with Arrotex Pharmaceuticals, while clinical results and regulatory decisions remain central to any eventual launch.

Market Setting

Recce Pharmaceuticals was trading higher on Wednesday 11 November 2026, up about 4.35% to around 36 cents in the early afternoon. Volume was about 124,000 shares, well below the roughly 595,000 four-week average shown on so the move reflects light trading. The company lodged no announcement today. The shares sit roughly 22% higher over the past month on after a run of corporate news.

The recent catalyst: an Arrotex licensing deal

On 22 October 2026 Recce lodged a price-sensitive announcement of a binding, exclusive licensing and commercialisation agreement with Arrotex Pharmaceuticals for its RECCE 327 gel, known as R327G, in Australia and New Zealand. the terms the same day.

Under the deal, Arrotex takes responsibility for registering and selling the product and meets the commercialisation costs in the two countries, including regulatory submissions, market access, marketing and sales. Recce keeps Manufacturing and supply rights and receives a share of gross Margin on Arrotex’s sales, paid quarterly. The size of that share has not been disclosed.

The agreement covers diabetic foot infections (DFIs) and acute bacterial skin and skin structure infections. Recce retains its intellectual property, rights outside Australia and New Zealand, and the ability to run Clinical Trials locally. the licence lasts until the later of the final Patent expiry or 10 years after the first Australian sale.

Any launch depends on successful Phase 3 results and regulatory approval, and no Revenue should be assumed until then.

What Recce does

Recce is a Sydney-based, late-stage clinical biotechnology company developing a class of synthetic anti-infectives aimed at antimicrobial-resistant bacteria. Its lead compound, RECCE 327, is being developed in topical, intravenous and other presentations. The Arrotex deal covers the topical gel in the two licensed countries; for other presentations such as intravenous and inhaled forms, the parties must negotiate in good faith, with an Arrotex right of first refusal if terms are not agreed within 90 days.

cited an estimate that about 50,000 Australians have diabetes-related foot ulcers, with another 300,000 considered at risk. DFIs can lead to hospitalisation, surgery or amputation if not effectively treated, which is the unmet need the company points to.

Other recent announcements

ASX records show several other items in recent weeks. On 20 October Recce lodged an announcement titled “Independent Review of Indonesian Phase 3 R327G Trial Data”, and on 30 October it released its quarterly activities and Cash Flow report.

Recce also held its Annual General Meeting on 6 November, with results of meeting and an AGM presentation lodged that day. On 4 November it announced the retirement of non-executive director Alistair McKeough and lodged an Options prospectus.

Key Operating Considerations

Recce is a pre-revenue clinical-stage company. ASX data puts its Market Value at roughly AUD 105 million to AUD 110 million, and its shares have ranged between 26.5 and 73 cents over the past 52 weeks, and them down about 45% so far in 2026. A deal with a distribution partner does not guarantee positive Phase 3 outcomes, approval or sales, and development-stage biotechs commonly need further funding, which can dilute existing shareholders.

Next Business Milestones

The company has said R327G is in registrational Phase 3 development for DFIs. No specific date for trial completion or regulatory filing has been confirmed in the information available. the company’s interim result as expected around late February 2027, though that is a forecast calendar date rather than a company-confirmed one.